Abbott SG&A increased by 19.5% to $3.74B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.2%, from $3.06B to $3.74B. Over 4 years (FY 2021 to FY 2025), SG&A shows relatively stable performance with a 2.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
Detailed definition
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Peer comparison
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
Metric ID:
is_selling_general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.73B | $2.77B | $3.05B | $2.79B | $2.76B | $2.73B | $2.97B | $2.76B | $2.74B | $2.72B | $2.72B | $2.96B | $2.94B | $2.90B | $2.91B | $3.06B | $3.09B | $3.05B | $3.13B | $3.74B |
| QoQ Change | — | +1.5% | +10.2% | -8.6% | -1.1% | -0.9% | +8.9% | -7.1% | -0.8% | -0.6% | +0.0% | +8.6% | -0.8% | -1.4% | +0.4% | +5.3% | +1.0% | -1.3% | +2.6% | +19.5% |
| YoY Change | — | — | — | — | +1.1% | -1.3% | -2.5% | -0.9% | -0.6% | -0.3% | -8.4% | +7.1% | +7.2% | +6.3% | +6.7% | +3.4% | +5.3% | +5.4% | +7.6% | +22.2% |
Range$2.72B – $3.74B
CAGR+6.9%
Avg YoY Growth+3.7%
Median YoY Growth+4.4%
Current Streak2 quarters growth
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Medical Devices | $1.29B | $1.39B | $1.39B | $1.39B | $1.39B |
| Nutritional Products | $576.00M | $585.00M | $515.00M | $435.00M | $563.00M |
| Diagnostic Products | $392.00M | $423.00M | $413.00M | $383.00M | $448.00M |
| Established Pharmaceuticals | $351.00M | $363.00M | $364.00M | $377.00M | $376.00M |
| Total | $3.06B | $3.09B | $3.05B | $3.13B | $3.74B |
SG&A at Other Companies
Frequently Asked Questions
- What is Abbott's sg&a?
- Abbott (ABT) reported sg&a of $3.74B in Q1 2026.
- How has Abbott's sg&a changed year-over-year?
- Abbott's sg&a increased by 22.2% year-over-year, from $3.06B to $3.74B.
- What is the long-term trend for Abbott's sg&a?
- Over 4 years (2021 to 2025), Abbott's sg&a has grown at a 2.2% compound annual growth rate (CAGR), from $11.32B to $12.33B.
- What does sg&a mean?
- The day-to-day costs of running the business and marketing its products.